Last update April 18, 2022
Very Low Risk
Bromhexine is metabolized into Ambroxol (Schaefer 2007 p72). Effectiveness of this drug has not been established (Prescrire 2017, INSALUD 2001). Oral administration two to three times a day.
At latest update, relevant published data on excretion into breast milk were not found.
Because of high serum protein-binding capacity (AEMPS 2016), excretion into breast milk in significant amount is seemingly unlikely.
Its low oral bioavailability (AEMPS 2016) causes a poor absorption into infant's serum as from breast milk, except in prematures and in the early neonatal period in which intestinal absorption may be increased.
Known adverse reactions are rare and mild. Ambroxol is used in children, infants and newborns. (Wei 2022, Kantar 2020, Xiang 2019, AEMPS 2016)
Secretion of prolactin and other hormones have not been affected by taking this medication. (Tuimala 1981)
Expert authors consider it safe during breastfeeding. (Schaefer 2007 p644)
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM